
NICE Endorses Funding for Ibrutinib in Patients With CLL
Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.
Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with the Burton’s tyrosine kinase inhibitor ibrutinib (Imbruvica) developed by Janssen, according to the National Institutes of Health and Care Excellence (NICE), which is the agency that monitors funding for healthcare in England and Wales.
In early 2016, Janssen UK received news that NICE had
Results from the RESONATE-2 trial could have swayed the decision in favor of the drug. At the 2016 annual meeting of the American Society of Hematology, Paul Barr, MD, assistant professor of medicine at the University of Rochester Wilmot Cancer Institute,
The company is now waiting to see whether NICE also clears ibrutinib for treating patients with mantle cell lymphoma and Waldenström's macroglobulinemia.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.